Exact Mass: 723.3512

Exact Mass Matches: 723.3512

Found 44 metabolites which its exact mass value is equals to given mass value 723.3512, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Trypanothione

(2S)-2-amino-4-{[(1R)-1-{[({3-[(4-{2-[(2R)-2-[(4S)-4-amino-4-carboxybutanamido]-3-sulfanylpropanamido]acetamido}butyl)amino]propyl}carbamoyl)methyl]carbamoyl}-2-sulfanylethyl]carbamoyl}butanoic acid

C27H49N9O10S2 (723.3044)

Leishmaniasis is a neglected disease caused by Leishmania, an intracellular protozoan parasite which possesses a unique thiol metabolism based on trypanothione. (PMID: 22928053) Trypanosomatids, the causative agents of several tropical diseases, rely on trypanothione as principal low molecular mass thiol, and their glutaredoxins readily react with the unique bis(glutathionyl) spermidine conjugate. (PMID: 22978520) Among the potential molecular target, Trypanothione reductase (TR) is considered an ideal enzyme since it is involved in the unique thiol-based metabolism observed in the Trypanosomatidae family and is a validated target for the search of antitrypanosomatidae drugs. (PMID: 23410156)

Phe Trp Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C42H41N7O5 (723.3169)

Trp Phe Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C42H41N7O5 (723.3169)

Trp Trp Phe Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C42H41N7O5 (723.3169)

Trp Trp Trp Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C42H41N7O5 (723.3169)

PHDdiA-PS

1-hexadecanoyl-2-(9-hydroxy-11-carboxy-10E-undecenoyl)-sn-glycero-3-phosphoserine

C34H62NO13P (723.3959)

Rendix

Dabigatran etexilate mesylate

C35H45N7O8S (723.305)

C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173066 - Direct Thrombin Inhibitor D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins

PYR-PHE-PHE-GLY-LEU-MET-NH2

C36H49N7O7S (723.3414)

Hydroxy-fumonisin C1

C33H57NO16 (723.3677)

(3E)-5-[{3-[(2S,5S)-5-(3-{[(2E)-5-hydroxy-3-methylpent-2-enoyl](oxido)amino}propyl)-3,6-dioxopiperazin-2-yl]propyl}(oxido)amino]-3-methyl-5-oxopent-3-en-1-yl N(5)-[(2E)-5-hydroxy-3-methylpent-2-enoyl]-N(5)-oxido-L-ornithinate

(3E)-5-[{3-[(2S,5S)-5-(3-{[(2E)-5-hydroxy-3-methylpent-2-enoyl](oxido)amino}propyl)-3,6-dioxopiperazin-2-yl]propyl}(oxido)amino]-3-methyl-5-oxopent-3-en-1-yl N(5)-[(2E)-5-hydroxy-3-methylpent-2-enoyl]-N(5)-oxido-L-ornithinate

C33H51N6O12-3 (723.3565)

BIS(GAMMA-glutamyl-cysteinyl-glycinyl)spermidine

C27H49N9O10S2 (723.3044)

Dabigatran etexilate mesylate

C35H45N7O8S (723.305)

PC 22:5/7:3;O3

C37H58NO11P (723.3747)

PC 22:6/7:2;O3

C37H58NO11P (723.3747)

PC 29:8;O3

C37H58NO11P (723.3747)

PE 20:5/12:3;O3

C37H58NO11P (723.3747)

PE 32:8;O3

C37H58NO11P (723.3747)

LNAPS 31:7;O

C37H58NO11P (723.3747)

PS 16:0/12:2;O3

C34H62NO13P (723.3959)

PS 18:4/13:3;O

C37H58NO11P (723.3747)

PS 20:0/8:2;O3

C34H62NO13P (723.3959)

PS 20:5/11:2;O

C37H58NO11P (723.3747)

PS 22:5/8:3;O2

C36H54NO12P (723.3383)

PS 22:6/7:3;O3

C35H50NO13P (723.302)

PS 22:6/8:2;O2

C36H54NO12P (723.3383)

PS 22:6/9:1;O

C37H58NO11P (723.3747)

PS 29:9;O3

C35H50NO13P (723.302)

PS 30:8;O2

C36H54NO12P (723.3383)

PS 31:7;O

C37H58NO11P (723.3747)

ST 29:4;O8;HexNAc

C37H57NO13 (723.383)

2-{[(1-{2-[(2-amino-1-hydroxy-3-phenylpropylidene)amino]-4-methylpentanoyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-n-[1-(c-hydroxycarbonimidoyl)-2-(4-hydroxyphenyl)ethyl]-3-(1h-indol-3-yl)propanimidic acid

2-{[(1-{2-[(2-amino-1-hydroxy-3-phenylpropylidene)amino]-4-methylpentanoyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-n-[1-(c-hydroxycarbonimidoyl)-2-(4-hydroxyphenyl)ethyl]-3-(1h-indol-3-yl)propanimidic acid

C40H49N7O6 (723.3744)

2-(2-{[(5r,6r,7s,9s,11r,16r,18r)-19-amino-6-[(3,4-dicarboxybutanoyl)oxy]-11,16,17,18-tetrahydroxy-5,9-dimethylnonadecan-7-yl]oxy}-2-oxoethyl)butanedioic acid

C33H57NO16 (723.3677)

1,1,3,3,3-pentabromoprop-1-en-2-yl 2,2,2-tribromoacetate

C5Br8O2 (723.3365)

8-benzyl-10,17,24-trihydroxy-26-methyl-15,22-bis(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,21(29),23-hexaen-7-one

8-benzyl-10,17,24-trihydroxy-26-methyl-15,22-bis(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,21(29),23-hexaen-7-one

C36H49N7O5S2 (723.3236)

(2r,8s,11s,15s,18s,22s,25s,26r)-8-benzyl-22-[(2r)-butan-2-yl]-15-[(2s)-butan-2-yl]-10,17,24-trihydroxy-26-methyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,21(29),23-hexaen-7-one

(2r,8s,11s,15s,18s,22s,25s,26r)-8-benzyl-22-[(2r)-butan-2-yl]-15-[(2s)-butan-2-yl]-10,17,24-trihydroxy-26-methyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,21(29),23-hexaen-7-one

C36H49N7O5S2 (723.3236)

(2s,8r,11r,15s,18r,22s,25s,26r)-8-benzyl-22-[(2r)-butan-2-yl]-15-[(2s)-butan-2-yl]-10,17,24-trihydroxy-26-methyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,21(29),23-hexaen-7-one

(2s,8r,11r,15s,18r,22s,25s,26r)-8-benzyl-22-[(2r)-butan-2-yl]-15-[(2s)-butan-2-yl]-10,17,24-trihydroxy-26-methyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,21(29),23-hexaen-7-one

C36H49N7O5S2 (723.3236)

(2s)-2-({[(2s)-1-[(2s)-2-{[(2s)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-4-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-n-[(1s)-1-(c-hydroxycarbonimidoyl)-2-(4-hydroxyphenyl)ethyl]-3-(1h-indol-3-yl)propanimidic acid

(2s)-2-({[(2s)-1-[(2s)-2-{[(2s)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-4-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-n-[(1s)-1-(c-hydroxycarbonimidoyl)-2-(4-hydroxyphenyl)ethyl]-3-(1h-indol-3-yl)propanimidic acid

C40H49N7O6 (723.3744)

(2s,8r,11r,15s,18r,22s,25s,26r)-8-benzyl-10,17,24-trihydroxy-26-methyl-15,22-bis(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,21(29),23-hexaen-7-one

(2s,8r,11r,15s,18r,22s,25s,26r)-8-benzyl-10,17,24-trihydroxy-26-methyl-15,22-bis(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,14(30),16,21(29),23-hexaen-7-one

C36H49N7O5S2 (723.3236)

2-[2-({19-amino-6-[(3,4-dicarboxybutanoyl)oxy]-11,16,17,18-tetrahydroxy-5,9-dimethylnonadecan-7-yl}oxy)-2-oxoethyl]butanedioic acid

C33H57NO16 (723.3677)